Baranyi · Scientific reports 2017 · cross-sectional study · n=?

Beta-trace Protein as a new non-invasive immunological Marker for Quinolinic Acid-induced impaired Blood-Brain Barrier Integrity.

Cited 22 times in the scientific literature.

Level 4 - case-series / case-control

Cross-sectional comparative study across clinical cohorts and healthy controls

PubMed 28276430 · doi:10.1038/srep43642 · record verified 2026-08-28

What was done

The authors investigated whether beta-trace protein (BTP), an established marker of cerebrospinal fluid leakage, could non-invasively reflect blood-brain barrier (BBB) integrity alterations associated with quinolinic acid. They evaluated three participant groups with varying degrees of immune activation: patients with hepatitis C virus (HCV) infection receiving interferon-alpha, patients with major depressive disorder, and healthy controls. Renal function (glomerular filtration rate) and age were accounted for, and group differences and predictors of BTP were analyzed using ANOVA and two-step hierarchical linear regression.

What was found

Quinolinic acid and BTP levels differed significantly across groups, with the highest concentrations observed in the HCV group compared to the depression and control groups (quinolinic acid: ANOVA F = 21.027, p < 0.001; BTP: ANOVA F = 6.792, p < 0.01). Hierarchical linear regression identified quinolinic acid, glomerular filtration rate, and age as significant predictors of BTP levels. Absolute concentration values, effect sizes, and regression coefficients were not reported in the abstract.

Why it matters

This study suggests that circulating BTP may serve as a non-invasive peripheral proxy for neuroinflammation-associated BBB permeability changes linked to quinolinic acid.

Limits

The abstract omits total sample size (n) and group breakdowns. The cross-sectional design precludes establishing causal relationships between quinolinic acid, BTP elevation, and BBB disruption. Direct confirmation of BBB breakdown (such as CSF-to-serum albumin ratio or neuroimaging) was not reported in the abstract to validate BTP against a gold standard.

Cited by